Molecular Features of Response to Palbociclib + Fulvestrant ± Inavolisib in Hormone Receptor–positive, HER2-negative, PIK3CA-mutated Advanced Breast Cancer as Assessed from Baseline Circulating Tumor DNA in the Pivotal Phase 3 INAVO120 Trial Inavolisib plus palbociclib and fulvestrant is approved for the treatment of PIK3CA-mutated, hormone...
Read MoreResearch Summary: Capivasertib is a potent, selective inhibitor of all three protein kinase B (AKT1/2/3) isoforms. The phosphoinositide 3- kinase/protein kinase B pathway is frequently overactivated in many solid tumors, including hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) breast cancer. In the...
Read MoreESMO 2025 Congress on October 17–21, 2025. Capivasertib plus fulvestrant as first- and second-line endocrine-based therapy in PIK3CA/AKT1/PTEN-altered hormone receptor–positive advanced breast cancer: subgroup analysis from the Phase III CAPItello-291 trial. Researchers analyzed data from the Phase III CAPItello-291 trial to determine the efficacy and...
Read MoreCapivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the Phase III CAPItello-291 trial Tokunaga E, Iwata H, Itoh M, et al. Breast Cancer. 2025;32(1):132–143. Summary. The Phase III CAPItello-291 trial showed that capivasertib plus...
Read MoreStephen Johnston, a medical oncologist at the Royal Marsden Hospital in London, outlines the benefits of CDK4/6 inhibitors plus endocrine therapy in patients with hormone positive, HER2-negative breast cancer. This is especially important for patients with high-risk disease, where adding another therapy could decrease their...
Read MoreResearch Summary: Estrogen receptor–positive (ER+) breast cancer is primarily driven by signaling through estrogen receptor α, a nuclear hormone receptor that regulates transcriptional pathways promoting tumor growth and survival. Endocrine therapies targeting ER, including selective estrogen receptor modulators (SERMs), aromatase inhibitors, and selective estrogen receptor...
Read MoreImlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): an indirect treatment comparison (ITC) of three Phase 3 trials. In the EMBER-3 trial, combination therapy with imlunestrant and abemaciclib was shown to...
Read More©2026 Oncology Matrix. All Rights Reserved.
